—2024—

The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
In KRAS: Methods and Protocols (Stephen A.G. and Esposito, D Editors), Springer, 2024. Methods in Molecular Biology. Vol 2797.

Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
Ito S, Pandya A, Hauser RG, Krishnamurti L, Stites E, Tormey C, Krumholz HM, Hendrickson JE, Goshua G
American Journal of Hematology. 2024 Apr;99(4):570-576.

—2023—

Theoretical analysis reveals a role for RAF conformational autoinhibition in paradoxical activation.
Mendiratta G and Stites EC
Elife. 2023 Oct 12;12:e82739.

Computational Random Mutagenesis to Investigate RAS Mutant Signaling.
Stites EC
In Computational Modeling of Signaling Networks (Nguyen, L.K. Editor), Springer, 2023. Methods in Molecular Biology. Vol 2634.

Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders.
Baglaenko Y, Wagner C, Bhoj VG, Brodin P, Gershwin ME, Graham D, Invernizzi P, Kidd KK, Korsunsky I, Levy M, Mammen AL, Nizet V, Ramirez-Valle F, Stites EC, Williams MS, Wilson M, Rose NR, Ladd V, Sirota M
Cambridge Prisms: Precision Medicine. 2023 May 11:1:e25.

—2022—

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP.
McFall T,  Trogdon T, Guizar AC, Langenheim JF, Sisk-Hackworth L, Stites EC
npj Precision Oncology. 2022 Nov 23;6(1):86.

Therapeutic targeting of RAS mutant cancers.
Stites EC, Paskvan K, Kato S. 
Elements in Molecular Oncology. 2022 Sept 15.

How often is each gene mutated within the cancer patient population? 
Mendiratta G, Jones MK, Stites EC.
Molecular & Cellular Oncology. 2022 May 1.

—2021—

Cancer gene mutation frequencies for the U.S. population. 
Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. 
Nature Communications. 2021 Oct 13;12(1):5961.

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.
McFall T, Stites EC. 
Cell Reports. 2021 Dec 14;37(11):110096.

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Kato S*, McFall T*, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E#, Kurzrock R#.
The Oncologist. 2021 Apr;26(4):e530-e536. (* and #, equal contribution)

Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.
Stites EC
In Ras Activity and Signaling (Rubio I, Prior I, Editors), Springer, 2021.  Methods Molecular Biology.  Vol 2262. 

—2020—

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.
McFall T, Schomburg NK, *Rossman KL, *Stites EC.
Cell Communication and Signaling. 2020 Nov 5;18(1):179. (*equal contribution)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R.
Nature Communications. 2020 Oct 2;11(1):4965.

The Interpretation of SARS-CoV-2 Diagnostic Tests.  
Stites EC, Wilen CB.
Med. 2020 Aug 21.

A mechanism for the response of KRAS G13D expressing colorectal cancers to EGFR inhibitors. 
McFall T, Stites EC. 
Molecular & Cellular Oncology.  2020 Jan 15.

—2019—

A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. 
McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. 
Science Signaling. 2019 Sep 24;12(600).

Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor.
Erickson KE, Rukhlenko OS, Shahinuzzaman MD, Slavkova KP, Lin YT, Suderman R, Stites EC, Anghel M, Posner RG, Barua D, Kholodenko BN, Hlavacek WS. 
PLoS Computational Biology. 2019 Jan 17;15(1):e1006706.

—2018—

Tumor-Immune Dynamics with an Immune Checkpoint Inhibitor. 
Nikolopoulou E, Johnson LR, Harris D, Nagy JD, Stites EC, and Kuang Y. 
Letters in Biomathematics, 2018, 5 (sup1), S137-S159.

A quantitative systems pharmacology analysis of KRAS G12C covalent inhibitors.
Stites EC, Shaw AS.
CPT Pharmacometrics & Systems Pharmacology. 2018 Feb 27.

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F.
American Journal of Medical Genetics Part A. 2018 Oct 10:e40632.

—2017—

A Phase II Trial of Personalized Cytotoxic Therapy Based on Tumor Immunohistochemistry in Previously Treated Metastatic Pancreatic Cancer Patients.
Ramanathan RK, Weiss GJ, Posner R, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. 
Journal of Gastroenterological Oncology, 2017 Dec;8(6):925-935.

—Pre-2017—

Use of Mechanistic Models to Integrate and Analyze Multiple Proteomic Datasets. 
Stites EC, Aziz M, Creamer MS, Von Hoff DD, Hlavacek WS, Posner RP. 
Biophysical Journal. 2015 Apr 7;108(7):1819-29.

Cooperation between Noncanonical Ras Network Mutations.
Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS. * co-first authors
Cell Reports. 2015 Jan 20. pii: S2211-1247(14)01064-X.

Allosteric activation of RAF kinases. 
Hu J, Stites EC, Yu H, Germino E, Shibatsu H, Stork PJ, Kornev AP, Taylor SS, Shaw AS. 
Cell. 2013 Aug 29;154(5):1036-46.

Innovations of the rule-based modeling approach.
L. A. Chylek, E. C. Stites, R. G. Posner and W. S. Hlavacek
In Systems Biology: Integrative Biology and Simulation Tools, Vol. 1, Ch. 9, pp. 273-300 (A. Prokop and B. Csukás, Editors), Springer, Dordrecht. 2013

Chemical kinetic models to investigate cancer biology and impact cancer medicine. 
Stites EC. 
Physical Biology.  2013 Feb 13;10(2):026004.

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. 
Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. 
PLoS One. 2012;7(10):e43192.

A computational model for ErbB receptor signaling that captures the phosphorylation kinetics of individual sites in proteins. 
Creamer MS, Stites EC, Aziz M, Cahill J, Tan CW, Berens ME, Han H, Bussey KJ, Von Hoff DD, Hlavacek WS, Posner RP. 
BMC Systems Biology. 2012 Aug 22;6(1):107.

The response of cancer to BRAF inhibition underscores the importance of cancer systems biology. 
Stites EC. 
Science Signaling. 2012 Oct 16;5(246):pe46.

Mathematical investigation of how oncogenic Ras mutants promote Ras signaling. 
Stites EC, Ravichandran KS. 
In Computational Modeling of Signaling Networks (Liu X, Betterton MD, Editors), Springer, 2012.  Methods in Molecular Biology Vol. 880.

Mechanistic modeling of oncogenic Ras signaling. 
Stites EC, Ravichandran KS. 
Wiley Interdisciplinary Reviews: Systems Biology and Medicine.  2012 Jan;4(1):117-27.

Modeling membrane localization: case study of a Ras signaling model. 
Stites EC. 
Advances in Computational Biology.  Advances in Experimental and Medical Biology. 2010;680:661-7. 

A systems perspective of Ras signaling in cancer. 
Stites EC, Ravichandran KS. 
Clinical Cancer Research.  2009 Mar 1; 15(5):1510-3.

Network analysis of oncogenic Ras activation in cancer. 
Stites EC, Trampont PC, Ma Z, Ravichandran KS. 
Science.  2007 Oct 19; 318 (5849); 463-7.

Sensitivity and versatility of an adaptive system for controlling cyclic movements using functional neuromuscular stimulation. 
Stites EC, Abbas JJ. 
IEEE Transactions in Biomedical Engineering. 2000 Sep; 47(9):1287-92.